ArticleAsian Pacific journal of cancer prevention : APJCP2026
Incidence and Risk Factors Associated with Platinum Derivative Chemotherapy-Induced Peripheral Neuropathy during Antineoplastic Treatment.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study retrospectively analyzed the incidence and risk factors associated with platinum-induced sensory peripheral neuropathy (PSPN).
methodsBefore each chemotherapy cycle, patients were routinely evaluated for the presence and severity of PSPN based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which ranges from 0 to 4. Information from two years of evaluations was collected, and patient medical records were reviewed to obtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapy protocol, history of head and neck radiotherapy, and overall survival. The X2 test, multinomial logistic regression, and Kaplan-Meier curves were used for statistical analysis (SPSS 20.0, p < 0.05).
resultsAmong 3,140 patients, 16,878 events were evaluated, with 7,187 (42.58%), 5,514 (32.67%), and 4,177 (24.75%) patients treated with cisplatin, carboplatin, or oxaliplatin, respectively. The incidence of any event of PSPN was 98.85% and 1867 (11.16%) showed scores two or higher (PSNP interfering with activities of daily living (ADL). Carboplatin and oxaliplatin (p<0.001), ≥5 CT cycles (p<0.001), body mass index >25 (p=0.005), advanced T (p<0.001), N (p=0.025) and M (p=0.010) clinical stages as well as association with capecitabine (p=0.021), paclitaxel (p=0.027) or vinorelbine (p=0.031) significantly increased risk of PSNP interfering in ADL. Over 48 months of evaluation, overall survival was 87.3% (n = 2741/3140), and PSNP interfering with ADLs significantly increased the risk of death by 1.52-fold (95% CI = 1.19-1.95, p = 0.001).
conclusionPCPN has a high incidence, and significant risk factors include BMI, age, number of CT cycles, advanced stages, and associations with capecitabine, paclitaxel, and vinorelbine, all of which are associated with lower overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.